lenacapavir
Selected indexed studies
- Lenacapavir: a first-in-class HIV-1 capsid inhibitor. (Curr Opin HIV AIDS, 2022) [PMID:34871187]
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (N Engl J Med, 2024) [PMID:39046157]
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. (N Engl J Med, 2025) [PMID:39602624]
_Worker-drafted node — pending editorial review._
Connections
lenacapavir is a side effect of
Sources
- Lenacapavir: a first-in-class HIV-1 capsid inhibitor. (2022) pubmed
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (2024) pubmed
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. (2025) pubmed
- Lenacapavir: A novel injectable HIV-1 capsid inhibitor. (2024) pubmed
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. (2022) pubmed
- Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis. (2025) pubmed
- Lenacapavir. (2012) pubmed
- Lenacapavir. (2006) pubmed
- Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention. (2025) pubmed
- Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. (2023) pubmed